Abstract
In celiac disease, the ingestion of gluten-containing cereals, such as wheat, rye, and barley, results in small-bowel mucosal inflammation and villous atrophy with crypt hyperplasia. The prevalence of the condition may be as high as 1% in the adult population. The disease can also embrace various extraintestinal manifestations, of which dermatitis herpetiformis is the best known. Earlier, dermatitis herpetiformis was considered a skin disease occurring often concomitantly with celiac disease. At present, a body of evidence shows that dermatitis herpetiformis is a cutaneous manifestation of celiac disease, and affects approximately 25% of patients with celiac disease. Both conditions can appear in the same family and are closely linked to HLA class II locus in chromosome 6; 90% of patients have HLA DQ2 and, almost all the remainder, HLA DQ8. All patients with dermatitis herpetiformis have at least some-degree of mucosal inflammation or lesion consistent with celiac disease. The etiology of celiac disease in not fully understood, but tissue transglutaminase seems to be the predominant autoantigen both in the intestine and the skin. Serum antibodies against tissue transglutaminase can be used in the serologic screening and follow-up of dietary compliance of patients with celiac disease. Gluten-free diet is essential in the treatment of both conditions, and oral dapsone is usually needed in newly detected dermatitis herpetiformis in order to alleviate symptoms. Oral mucosal lesions, alopecia areata, and vitiligo probably occur more frequently in patients with dermatitis herpetiformis than in the general population. By contrast, the reported association of celiac disease with psoriasis seems to be coincidental.
Similar content being viewed by others
References
Fasano A., Catassi C. Current approaches to diagnosis and treatment of celiac disease: an evolving spectrum. Gastroenterology 2001; 120: 636–651
Moi H. Incidence and prevalence of dermatitis herpetiformis in a county in central Sweden with comments on the course of the disease and IgA deposits as a diagnostic criterion. Acta Derm Venereol 1984; 64: 144–150
Gawkrodger D.J.G., Blackwell J.N., Gilmour H.K., et al. Dermatitis herpetiformis, diagnosis, diet and demography. Gut 1984; 25: 151–157
Egan C.A., O’Loughlin S., Gormally P., et al. Dermatitis herpetiformis: a review of fifty-four patients. Ir J Med Sci 1997; 166: 241–244
Sigurgeirsson B., Agnarsson B.A., Lindelöf B. Risk of lymphoma in patients with dermatitis herpetiformis. BMJ 1994; 308: 13–15
Collin P., Reunala T., Rasmussen M., et al. High incidence and prevalence of adult coeliac disease: augmented diagnostic approach. Scand J Gastroenterol 1997; 32: 1129–1133
Hall R.P., Clark R.E., Ward F.E. Dermatitis herpetiformis in two American blacks: HLA type and clinical characteristics. J Am Acad Dermatol 1990; 22: 436–439
Shibahara M., Nanko H., Shimizu M., et al. Dermatis herpetiformis in Japan: an update. Dermatology 2002; 204: 37–42
Karpati S., Kosnai I., Verkasalo M., et al. HLA antigens, jejunal morphology and associated diseases in children with dermatitis herpetiformis. Acta Paediatr Scand 1986; 75: 297–301
Ermacora E., Prampolini L., Tribbia G., et al. Long-term follow-up of dermatitis herpetiformis children. J Am Acad Dermatol 1986; 15: 24–30
Mäki M., Collin P. Coeliac disease. Lancet 1997; 349: 1755–1759
Hervonen K., Hakanen M., Kaukinen K., et al. First-degree relatives are frequently affected in coeliac disease and dermatitis herpetiformis. Scand J Gastroenterol 2002; 37: 51–55
Meyer L.J., Zone J.J. Familial incidence of dermatitis herpetiformis. J Am Acad Dermatol 1987; 17: 643–647
Lähteenoja H., Irjala K., Viander M., et al. Oral mucosa is frequently affected in patients with dermatitis herpetiformis. Arch Dermatol 1998; 134: 756–758
Patinen P., Hietanen J., Malmström M., et al. Iodine and gliadin challenge on oral mucosa in dermatitis herpetiformis. Acta Derm Venereol 2002; 82: 86–89
van der Meer R. Granular deposits of immunoglobulins in the skin of the patients with dermatitis herpetiformis. Br J Dermatol 1969; 81: 493–503
Zone J.J., Meyer L.J., Petersen M.J. Deposition of granular IgA relative to clinical lesions in dermatitis herpetiformis. Arch Dermatol 1996; 132: 912–918
Beutner E.H., Chorzelski T.B., Reunala T.L., et al. Immunopathology of dermatitis herpetiformis. Clin Dermatol 1992; 9: 295–311
Guide S.V., Marinkovich M.P. Linear IgA bullous dermatosis. Clin Dermatol 2001; 19: 719–727
Alexander J.O. Dermatitis herpetiformis: major problems in dermatology. Vol. 4. London: WB Saunders, 1975
Chorzelski T.P., Jablonska S., Maciejowska E. Linear IgA bullous dermatosis of adults. Clin Dermatol 1992; 9: 383–392
Logan R.F.A., Tucker G., Rifkind E.A., et al. Changes in clinical features of coeliac disease in adults in Edinburgh and the Lothians 1960–1979. BMJ 1983; 286: 95–97
Reunala T., Kosnai I., Karpati S., et al. Dermatitis herpetiformis: jejunal findings and skin response to gluten-free diet. Arch Dis Child 1984; 59: 517–522
Dieterich W., Ehnis T., Bauer M., et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997; 3: 797–801
Lundin K.E.A., Scott H., Hansen T., et al. Gliadin-specific, HLA-DQ (a1*0501, ß1*0201) restricted T cells isolated from the small intestinal mucosa of celiac disease patients. J Exp Med 1993; 178: 87–96
Molberg O., McAdam S.N., Korner R., et al. Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease. Nat Med 1998; 4: 713–717
Schuppan D. Current concepts of celiac disease pathogenesis. Gastroenterology 2000; 119: 234–242
Aeschlimann D., Koeller M.K., Allen-Hoffmann B.L., et al. Isolation of a cDNA encoding a novel member of the transglutaminase gene family from human keratinocytes. J Biol Chem 1998; 273: 3452–3460
Raghunath M., Höpfner B., Aeschlimann D., et al. Cross-linking of the dermoepidermal junction of skin regenerating from keratinocyte aurografts. J Clin Invest 1996; 98: 1174–1184
Sárdy M., Kárpáti S., Merkl B., et al. Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis. J Exp Med 2002; 195: 747–757
Vogelsang H., Genser D., Wyatt J., et al. Screening for celiac disease: a prospective study on the value of noninvasive tests. Am J Gastroenterol 1995; 90: 394–398
Sulkanen S., Collin P., Laurila K., et al. IgA- and IgG-class antihuman umbilical cord antibody tests in adult coeliac disease. Scand J Gastroenterol 1998; 33: 251–254
Ladinser B., Rossipal E., Pittschieler K. Endomysium antibodies in coeliac disease: an improved method. Gut 1994; 35: 776–778
Dieterich W., Laag E., Schopper H., et al. Autoantibodies to tissue transglutaminase as predictors of celiac disease. Gastroenterology 1998; 115: 1317–1321
Sulkanen S., Halttunen T., Laurila K., et al. Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease. Gastroenterology 1998; 115: 1322–1328
Collin P., Mäki M., Keyriläinen O., et al. Selective IgA deficiency and coeliac disease. Scand J Gastroenterol 1992; 27: 367–371
Dieterich W., Laag E., Bruckner-Tuderman L., et al. Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis. J Invest Dermatol 1999; 113: 133–136
Koop I., Ilchmann R., Izzi L., et al. Detection of autoantibodies against tissue transglutaminase in patients with celiac disease and dermatitis herpetiformis. Am J Gastroenterol 2000; 95: 2009–2014
Aine L. Permanent tooth dental enamel defects leading to the diagnosis of coeliac disease. Br Dent J 1994; 177: 253–254
Ballinger A., Hughes C., Kumar P., et al. Dental enamel defects in coeliac disease. Lancet 1994; 343: 230–231
Aine L. Coeliac-type permanent tooth enamel defects. Ann Med 1996; 28: 9–12
Hadjivassiliou M., Grunewald R.A., Chattopadhyay A.K., et al. Clinical, radiological, neuropscyhological, and neuropathological characteristics of gluten ataxia. Lancet 1998; 352: 1582–1585
Valdimarsson T., Toss G., Ross I., et al. Bone mineral density in coeliac disease. Scand J Gastroenterol 1994; 29: 457–461
Mora S., Barera G., Beccio S., et al. Bone density and bone metabolism are normal after long-term gluten-free diet in young celiac patients. Am J Gastroenterol 1999; 94: 398–403
Marsh M.N. Bone disease and gluten sensitivity: time to act, to treat, and to prevent. Am J Gastroenterol 1994; 89: 2105–2107
Reunala T., Collin P. Diseases associated with dermatitis herpetiformis. Br J Dermatol 1997; 136: 315–318
Zettinig G., Weissel M., Flores J., et al. Dermatitis herpetiformis is associated with atrophic but not with goitrous variant of Hashimoto’s thyroiditis. Eur J Clin Invest 2000; 30: 53–57
Cunningham M.J., Zone J.J. Thyroid abnormalities in dermatitis herpetiformis. Ann Intern Med 1985; 102: 194–196
Weetman A.P., Burrin J.M., Mackay D., et al. The prevalence of thyroid autoantibodies in dermatitis herpetiformis. Br J Dermatol 1988; 118: 377–383
Gaspari A.A., Huang C.-M., Davey R.J., et al. Prevalence of thyroid abnormalities in patients with dermatitis herpetiformis and in control subjects with HLA-B8/-DR3. Am J Med 1990; 88: 145–150
Collin P., Kaukinen K., Välimäki M., et al. Endocrinological disorders and celiac disease. Endocr Rev 2002; 23: 464–483
Fry L., Seah P.P., Riches D.J., et al. Clearance of skin lesions in dermatitis herpetiformis after gluten withdrawal. Lancet 1973; I: 288–291
Reunala T., Blomqvist K., Tarpila S., et al. Gluten-free diet in dermatitis herpetiformis: I. clinical response of skin lesions in 81 patients. Br J Dermatol 1977; 97: 473–480
Garioch J.J., Lewis H.M., Sargent S.A., et al. 25 years experience of a gluten-free diet in the treatment of dermatitis herpetiformis. Br J Dermatol 1994; 131: 541–545
Janatuinen E.K., Pikkarainen P.H., Kemppainen T.A., et al. A comparison of diets with and without oats in adults with celiac disease. N Engl J Med 1995; 333: 1033–1037
Hardman C.M., Garioch J.J., Leonard J.N., et al. Absence of toxicity of oats in patients with dermatitis herpetiformis. N Engl J Med 1997; 337: 1884–1887
Reunala T., Collin P., Holm K., et al. Tolerance to oats in dermatitis herpetiformis. Gut 1998; 43: 490–493
Leonard J.N., Fry L. Treatment and management of dermatitis herpetiformis. Clin Dermatol 1992; 9: 403–408
Collin P., Pukkala E., Reunala T. Malignancy and survival in dermatitis herpetiformis: a comparison with coeliac disease. Gut 1996; 38: 528–530
Leonard J.N., Tucker W.F., Fry J.S., et al. Increased incidence of malignancy in dermatitis herpetiformis. BMJ 1983; 286: 16–18
Lewis H.M., Reunala T.L., Garioch J.J., et al. Protective effect of gluten-free diet against development of lymphoma in dermatitis herpetiformis. Br J Dermatol 1996; 135: 363–367
Marsden R.A. The treatment of benign bullous dermatosis of childhood, and dermatitis herpetiformis and bullous pemphigoid beginning in childhood. Clin Exp Dermatol 1982; 7 (6): 653–663
Prussick R., Ali M.A.M., Rosenthal D., et al. The protective effect of vitamin E on the hemolysis associated with dapsone treatment in patients with dermatitis herpetiformis. Arch Dermatol 1992; 128: 210–213
Hörnsten P., Keisu M., Wiholm B.-E. The incidence of agranulosytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988. Arch Dermatol 1990; 126: 919–922
Coleman M.D. Dapsone mediated agranulocytosis: risks, possible mechanism and prevention. Toxicology 2001; 162: 53–60
Kastrup W., Mobacken H., Stockbrugger R., et al. Malbabsorption of vitamin B12 in dermatitis herpetiformis and its association with pernicious anemia. Acta Med Scand 1986; 220: 261–268
Reunala T., Chorzelski T.P., Viander M., et al. IgA anti-endomysial antibodies in dermatitis herpetiformis: correlation with jejunal morphology, gluten-free diet and antigliadin antibodies. Br J Dermatol 1987; 117: 185–191
Ventura A., Magazzu G., Greco L. Duration of exposure to gluten and risk for autoimmune disorders in patients with celiac disease. Gastroenterology 1999; 117: 297–303
Ferguson R., Basu M.K., Asquith P., et al. Jejunal mucosal abnormalities in patients with recurrent aphthous ulceration. BMJ 1976; 1: 11–13
Ferguson M.M., Wray D., Carmichael H.A., et al. Coeliac disease associated with recurrent aphthae. Gut 1980; 21: 223–226
Wray D. Gluten-sensitive recurrent aphthous stomatitis. Dig Dis Sci 1981; 26: 737–740
Jokinen J., Peters U., Mäki M., et al. Celiac sprue in patients with chronic oral mucosal symptoms. J Clin Gastroenterol 1998; 26: 23–26
Corazza G.R., Andreani M.L., Venturo N., et al. Celiac disease and alopecia areata: report of a new association. Gastroenterology 1995; 109: 1333–1337
Volta U., Bardazzi F., Zauli D., et al. Serological screening for coeliac disease in vitiligo and alopecia areata. Br J Dermatol 1997; 136: 801–802
Amato L., Gallerani I., Fuligini A., et al. Dermatitis herpetiformis and vitiligo: report a case and review of literature. J Dermatol 2002; 27: 462–466
de Vos R.J., de Boer W.A., Haas F.D. Is there a relationship between psoriasis and coeliac disease [letter]? J Intern Med 1995; 237: 118
Lindqvist U., Rudsander 0.A., Bostrom 0.A., et al. IgA antibodies to gliadin and coeliac disease in psoriatic atrhritis. Rheumatology 2002; 41: 31–37
Acknowledgments
Supported by a grant from the Medical Research Fund of Tampere University Hospital.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Collin, P., Reunala, T. Recognition and Management of the Cutaneous Manifestations of Celiac Disease. Am J Clin Dermatol 4, 13–20 (2003). https://doi.org/10.2165/00128071-200304010-00002
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128071-200304010-00002